A lively thread in early May saw patients and clinicians dissecting claims that topical tacrolimus, already familiar as a calcineurin-inhibitor for eczema, might “make lymphedema disappear.” Posters shared before-and-after images and a link to a pending NIH-registered phase I/II study, while vascular surgeons in the comments warned that the photos likely showed postoperative debulking and not drug action. Geneticists in the group reminded readers that fibrosis and adipose remodeling—not inflammation alone—drive chronic limb volume, making a single agent unlikely to be curative. Consensus: tacrolimus may calm dermatitis and reduce local cytokine load, but durable edema control still hinges on compression and, in selected cases, microsurgical bypass or VLNT.
24 May 2025 — la discussione potrebbe continuare visita reddit
